Neuromuscular Disorders
Conference Coverage
Approved Therapy for ALS Is Withdrawn When New Study Shows No Benefit
A newly completed trial has led to market withdrawal of the ALS therapy PB&TURSO.
Conference Coverage
Positive Results From Phase 2 Trial Support Potential New Option for Control of CIDP
Efgartigimod PC20 trial meets the primary endpoint with favorable safety profile.
Conference Coverage
Prominent Researcher Describes Pivot From ALS Treatment to Prevention
After a long career that has included participation in a series of promising but failed treatment trials for ALS, a prominent researcher has...
From the Journals
Chronic Pain Linked to Accelerated Brain Aging
The acceleration in brain aging was largely driven by the hippocampus and predicted memory decline and incident dementia during follow-up.
Latest News
Billions Spent on DMD Meds Despite Scant Proof of Efficacy
The findings point to the importance of follow-up on drugs that are approved with preliminary evidence.
Conference Coverage
Neurologists Read Signs to Diagnose Functional Neurological Disorders
With training and experience, neurologists can learn the characteristics pointing to an accurate diagnosis of functional neurological disorder.
Conference Coverage
Essential Tremor Tied to a Threefold Increased Risk for Dementia
During the follow-up, the cumulative prevalence of dementia was 18.5%, and the average annual conversion rate of MCI to dementia was 12.2% —...
Literature Review
Promising Results for Investigational Myasthenia Gravis Drug
After 6 weeks of treatment, patients reported nearly 60% sustained improvement in daily activities.
From the Journals
Chronic Fatigue Syndrome and Fibromyalgia: A Single Disease Entity?
“The sum of these results does not support the hypothesis that ME/CFS and ME/CFS+FM are distinct entities, as currently defined.”
Latest News
Exercise improves physical and cognitive health in Down syndrome
Walking, which is easy and inexpensive, is recommended.
Conference Coverage
Novel myasthenia gravis therapies bring opportunities, challenges
Minimal disease manifestation is meaningful for patients, but should be weighed against potential side effects.